<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03411122</url>
  </required_header>
  <id_info>
    <org_study_id>BBI608-102</org_study_id>
    <nct_id>NCT03411122</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, single-center, open-label, single-sequence, 3-period, PK drug interaction&#xD;
      study evaluating the effect of napabucasin in healthy volunteers on the single-dose PK of&#xD;
      several cytochrome P450 (CYP450) probe drugs as well as a BCRP substrate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Actual">January 23, 2018</completion_date>
  <primary_completion_date type="Actual">January 23, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics for napabucasin by assessing plasma concentration</measure>
    <time_frame>Predose and up to 7 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for probe drugs by assessing plasma concentration</measure>
    <time_frame>Predose and up to 7 days post dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Drug-drug Interactions</condition>
  <arm_group>
    <arm_group_label>Single-sequence 3-period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: napabucasin 240 mg BID on days 1-2 Period 2: cytochrome P450 probe drugs during days 1-4 Period 3: napabucasin 240 mg BID on days 1-11, cytochrome P450 probe drugs during days 6-9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>napabucasin</intervention_name>
    <description>Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.</description>
    <arm_group_label>Single-sequence 3-period</arm_group_label>
    <other_name>BBI-608</other_name>
    <other_name>BBI608</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate</intervention_name>
    <description>CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.</description>
    <arm_group_label>Single-sequence 3-period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        A subject will be eligible for inclusion in this study only if all the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. An Institutional Review Board (IRB) approved informed consent is signed and dated&#xD;
             prior to any study-related activities.&#xD;
&#xD;
          2. Subject is between the ages of 18 and 45 years, inclusive.&#xD;
&#xD;
          3. Subject is a female of childbearing potential with a negative pregnancy test or has&#xD;
             documented surgical sterilization or is post-menopausal prior to Screening. All male&#xD;
             and female subjects must agree to use contraception while participating in the study&#xD;
             and for 30 days after their last dose of study drug unless surgically sterile or&#xD;
             post-menopausal.. It is the Investigator's responsibility for determining whether the&#xD;
             Subject has adequate birth control for study participation.&#xD;
&#xD;
          4. Subject has a body mass index between 18 and 34 kg/m^2 (weight/[height]^2).&#xD;
&#xD;
          5. Subject has normal (or abnormal and clinically insignificant according to the&#xD;
             Investigator) laboratory values at screening.&#xD;
&#xD;
          6. Subject is medically normal with no significant abnormalities at the baseline physical&#xD;
             examination.&#xD;
&#xD;
          7. Subject has the ability to understand the requirements of the study and a willingness&#xD;
             to comply with all study procedures.&#xD;
&#xD;
          8. Subject has not consumed and agrees to abstain from taking any dietary supplements,&#xD;
             herbal products, or non-prescription drugs (except as authorized by the Investigator&#xD;
             and Medical Monitor) for 14 days prior to CRU admission through Follow-Up.&#xD;
&#xD;
          9. Subject has not consumed and agrees to abstain from taking any prescription drugs&#xD;
             (except as authorized by the Investigator and Medical Monitor) during the 14 days&#xD;
             prior to CRU admission through Follow-Up.&#xD;
&#xD;
         10. Subject has not consumed alcohol-containing beverages for 3 days prior to CRU&#xD;
             admission and agrees not to consume alcohol through Follow-Up.&#xD;
&#xD;
         11. Subject has not consumed grapefruit, grapefruit juice, Seville oranges, and&#xD;
             grapefruit- or Seville orange containing products within the 14 days prior to CRU&#xD;
             admission and agrees not to consume grapefruit or grapefruit juice through Follow-Up.&#xD;
&#xD;
         12. Subject has not used tobacco- and nicotine-containing products within 2 months prior&#xD;
             to the CRU admission and agrees to abstain from using tobacco- and nicotine-containing&#xD;
             products through Follow-up.&#xD;
&#xD;
         13. Subject agrees to abstain from consuming caffeine- or chocolate-containing products&#xD;
             from 3 days prior to CRU admission through Follow-up.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        A Subject will not be eligible for inclusion in this study if any of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Subject has a history illicit drug abuse in the past year or current evidence of such&#xD;
             abuse in the opinion of the Investigator.&#xD;
&#xD;
          2. Subject has positive findings on urine drug screen.&#xD;
&#xD;
          3. Subject is positive for human immunodeficiency virus (HIV), hepatitis B and/or&#xD;
             hepatitis C on Screening assessments.&#xD;
&#xD;
          4. Subject is determined to be a poor metabolizer for CYP2C19, CYP2C9 and/or CYP2D6.&#xD;
&#xD;
          5. Subject has a QTcF &gt;450 msec (if male) or &gt;470 msec (if female) at Screening.&#xD;
&#xD;
          6. Subject is pregnant or lactating.&#xD;
&#xD;
          7. Subject has an acute illness within 1 week of CRU admission.&#xD;
&#xD;
          8. Subject has a hypersensitivity or allergy to napabucasin or any of the probe drugs, or&#xD;
             the ingredients of napabucasin or any of the probe drugs, or other clinically&#xD;
             significant allergies.&#xD;
&#xD;
          9. Subject has donated plasma within 7 days of drug administration.&#xD;
&#xD;
         10. Subject has donated 1 or more pints of blood (or equivalent blood loss) within 30 days&#xD;
             prior to drug administration.&#xD;
&#xD;
         11. Subject has a history of chronic Gastroesophageal reflux disease (GERD) or has used&#xD;
             omeprazole or other proton pump inhibitors within 3 months of Screening.&#xD;
&#xD;
         12. Subject has participated in an investigational drug study within the 30 days prior to&#xD;
             CRU admission.&#xD;
&#xD;
         13. Subject is an employee of the Investigator or study center, with direct involvement in&#xD;
             the proposed study or other studies under the direction of that Investigator or study&#xD;
             center, or a family member of the employees or the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Accel Research Sites</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Cytochrome P-450 Enzyme Inducers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

